Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination

We have studied the mechanism of apoptosis elicited by the farnesyltransferase inhibitor (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662) in human myeloma cell lines. Low concentrations of BMS-214662 efficiently inhibited protein farnesylation but did not affect the activation of Akt. BMS-214662 treatment increased levels of the BH3-only protein PUMA; induced proapoptotic conformational changes of Bax and Bak; reduced Mcl-1 levels; caused mitochondrial transmembrane potential loss; induced cytochrome c release, caspase activation, apoptosis-inducing factor (AIF) nuclear translocation, and phosphatidylserine exposure; and allowed the development of apoptotic morphology. Western blot analysis of cell extracts revealed the activation of caspases 2, 3, 8, and 9 upon treatment with BMS-214662. The general caspase inhibitor Z-VAD-fmk significantly prevented BMS-214662–induced death in U266 and RPMI 8226 cells but not in NCI-H929 cells. A mixture of selective caspase inhibitors for caspases 9 [N-benzyloxycarbonyl-Leu-Glu-His-Asp-fluoromethyl ketone (Z-LEHD-fmk)], 3 (Z-DEVD-fmk), and 6 (Z-VEID-fmk) approached the protective effect of Z-VAD upon cell death. However, Z-VAD-fmk did not prevent BMS-214662–induced Bax and Bak activation and decrease of Mcl-1 levels. According to its effect on cell death, Z-VAD-fmk inhibited nuclear translocation of AIF in RPMI 8226 and U266 but not in NCI-H929 cells. These results suggest that apoptosis triggered by BMS-214662 is initiated by a PUMA/Bax/Bak/Mcl-1–dependent mechanism. In some cell lines, Bax/Bak activation is not sufficient per se to induce mitochondrial failure and release of apoptogenic proteins, and so caspases need to be activated to facilitate apoptosis. After ΔΨm loss, execution of apoptosis was performed in all cases by a cytochrome c-enabled, caspase-9–triggered, caspase cascade and the nuclear action of AIF.

[1]  H. Yamaguchi,et al.  Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. , 2002, Cancer research.

[2]  L. Boise,et al.  R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways. , 2004, Molecular cancer therapeutics.

[3]  M. Kamphuis,et al.  Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. , 2003, Blood.

[4]  D. Grandér,et al.  Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to Doxorubicin* , 2002, The Journal of Biological Chemistry.

[5]  M. Morgan,et al.  Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? , 2000, Blood.

[6]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[7]  R. Bataille,et al.  Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells , 2002, Leukemia.

[8]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[9]  I. Gojo,et al.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma. , 2002, Blood.

[10]  F. Khuri,et al.  Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. , 2003, Cancer research.

[11]  A. Anel,et al.  Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia , 2002, Leukemia.

[12]  R. Bataille,et al.  The imbalance between Bim and Mcl‐1 expression controls the survival of human myeloma cells , 2004, European journal of immunology.

[13]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[14]  F. Lee,et al.  Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. , 2001, Cancer research.

[15]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[16]  S. Korsmeyer,et al.  Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death* , 1999, The Journal of Biological Chemistry.

[17]  F. Khuri,et al.  Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-κB Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-κB-regulated Gene Expression and Up-regulation of Apoptosis* , 2004, Journal of Biological Chemistry.

[18]  C. Erlichman,et al.  Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  W. Dalton,et al.  The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells , 2003, Leukemia.

[20]  J. D. Vos,et al.  A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells , 2003, Oncogene.

[21]  S. Sebti,et al.  Design of growth factor antagonists with antiangiogenic and antitumor properties , 2000, Oncogene.

[22]  L. Boise,et al.  Farnesyl Transferase Inhibitors Enhance Death Receptor Signals and Induce Apoptosis in Multiple Myeloma Cells , 2003, Leukemia & lymphoma.

[23]  A. Almasan,et al.  Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis , 2000, Cell Death and Differentiation.

[24]  Sheo B. Singh,et al.  Current progress on farnesyl protein transferase inhibitors. , 2002, Current opinion in drug discovery & development.

[25]  Javier Naval,et al.  Caspases are the main executioners of Fas-mediated apoptosis, irrespective of the ceramide signalling pathway , 1998, Cell Death and Differentiation.

[26]  K. Anderson,et al.  CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. , 2000, Blood.

[27]  C. F. Bennett,et al.  A Constitutive Cytoprotective Pathway Protects Endothelial Cells from Lipopolysaccharide-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[28]  B. Corfe,et al.  Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak , 2001, Oncogene.

[29]  J. Cidlowski,et al.  Activation of intrinsic and extrinsic pathways in apoptotic signaling during UV-C-induced death of Jurkat cells: the role of caspase inhibition. , 2004, Experimental cell research.

[30]  J. Gera,et al.  Downstream effectors of oncogenic ras in multiple myeloma cells. , 2003, Blood.

[31]  B. Corfe,et al.  Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis , 1999, The Journal of cell biology.

[32]  John Calvin Reed,et al.  Detection of multiple antigens on western blots. , 1996, Analytical biochemistry.

[33]  R. GonzálezBosch.  Treatment of multiple myeloma , 1959 .

[34]  R. Kurzrock,et al.  Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. , 2002, Seminars in hematology.

[35]  M. Martínez-Lorenzo,et al.  Doxorubicin‐induced apoptosis in human T‐cell leukemia is mediated by caspase‐3 activation in a Fas‐independent way , 1997, FEBS letters.

[36]  S. Grant,et al.  The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells , 2003, Leukemia.

[37]  G. Prendergast,et al.  Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB , 1999, Molecular and Cellular Biology.

[38]  G. Pons,et al.  Aspirin induces apoptosis through mitochondrial cytochrome c release , 2000, FEBS letters.

[39]  J. Trapani,et al.  A new quantitative assay for cytochrome c release in apoptotic cells , 2003, Cell Death and Differentiation.

[40]  A. Adjei,et al.  Farnesyl transferase inhibitors as anticancer agents. , 2002, European journal of cancer.

[41]  M. Urashima,et al.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. , 1997, Journal of immunology.

[42]  S. Hilsenbeck,et al.  Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. , 2003, Blood.